UCLA forms research collaboration with Yuyu Pharma to advance MS treatment

Through a new collaboration with a South Korean pharmaceutical company, UCLA scientists will participate in the process to develop a new drug to treat multiple sclerosis.UCLA and Yuyu Pharma will evaluate the efficacy and safety of drugs that have the potential to treat the debilitating disease.The collaboration was facilitated by theUCLA Technology Development Group, which manages UCLA ’s intellectual property and spearheads partnerships with private industry to commercialize UCLA research.“We are excited that Yuyu Pharma chose UCLA as its first academic institution partner in the U.S.,” said Amir Naiberg, UCLA associate vice chancellor and the CEO and president of the Technology Development Group.Leading the project for UCLA are Dr. Rhonda Voskuhl and Professor Michael Jung. Voskuhl is a physician, research scientist and UCLA ’s Jack H. Skirball Professor of Multiple Sclerosis Research. They have already developed drug candidates that have shown promise in lab tests and that may eventually be applicable for people with either relapsing-remitting or progressive multiple sclerosis.“I am very excited to advance my laboratory’s basic discovery of a novel approach to repair damage in the brain in multiple sclerosis,” said Voskuhl, who also is director of theUCLA Multiple Sclerosis Program. “Our team at UCLA in partnership with Yuyu aims to bring this to patients by sharing our unique and complementary areas of expertise.”Jung holds the University of California ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news